The past, present, and future of statin therapy

Reviews in Cardiovascular Medicine

Volumn 6, Issue 3, 2005, Pages 129-139

  Watson, Karol E ^a   Fonarow, Gregg C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Coronary heart disease; HDL cholesterol; LDL cholesterol; Safety; Statins; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; ETC 216; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PHENYTOIN; PLACEBO; PRAVASTATIN; RETINOID DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; TIROFIBAN; TORCETRAPIB; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; FLUSHING; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; METABOLIC SYNDROME X; MONOTHERAPY; MYALGIA; MYOPATHY; MYOSITIS; NEPHROTOXICITY; NONHUMAN; PLEIOTROPY; PREVALENCE; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; DRUG THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 26944503498     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Clark LT, Ferdinand KC, Flack JM, et al. Coronary heart disease in African Americans. Heart Dis. 2001;3:97-108.
2. Centers for Disease Control and Prevention. Disparities in premature deaths from heart disease - 50 states and the District of Columbia, 2001. MMWR Morb Mortal Wkly Rep. 2004;53: 121-125.
3. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, et al. Efficacy of a National Cholesterol Education Program Step 2 diet in normolipidemic and hyperlipidemic middle aged and elderly men and women. Arterioscler Thromb Vasc Biol. 1995;15:1079-1085.
4. Schaefer EJ, Lamon-Fava S, Ausman LM, et al. Individual variability in lipoprotein cholesterol response to National Cholesterol Education Program Step 2 diets. Am J Clin Nutr. 1997;65: 823-830.
5. Hunninghake DB, Stein FA, Dujorne CA, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Eng J Med. 1993; 328:1213-1219.
6. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33:1569-1582.
7. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582-587.
8. Jones PH, Hunninghake DB, Ferdinand KC, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004;26: 1388-1399.
9. Gaw A. HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins. Cardiovasc Drugs Ther. 2003;17: 53-62.
10. Davidson MH, Ose L, Frohlich J, et al. Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. Clin Cardiol. 2003;26:509-514.
11. Randall OS, Feseha HB, Illoh K, et al. Response of lipoprotein(a) levels to therapeutic life-style change in obese African-Americans. Atherosclerosis. 2004;172:155-160.
12. Futterman LG, Lemberg L. Statin pleiotropy: fact or fiction? Am J Crit Care. 2004;13:244-249.
13. The 4S Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
14. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med. 1995;333:1301-1307.
15. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335: 1001-1009.
16. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615-1622.
17. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
18. HPS Investigators. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J. 1999;20:725-741.
19. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288: 2998-3007.
20. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
21. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
22. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
23. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
24. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080.
25. de Lemos JA, Blazing MA, Wiviott SD, et al. Early invasive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307-1316.
26. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
27. Rosenson RS. Biological basis for statin therapy in stroke prevention. Curr Opin Neurol. 2000; 13:57-62.
28. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;106: 1024-1028.
29. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf. 2002;25:649-663.
30. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681-1690.
31. Vidt DG, Cressman MD, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology. 2004;102:52-60.
32. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585-2590.
33. Jacobson TA. Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. Exp Opin Drug Saf. 2003; 2:269-286.
34. Beringer PM, Slaughter RL. Transporters and their impact on drug disposition. Ann Pharmacother. 2005;39:1097-1108.
35. Ballantyne CM. Role of selective cholesterol absorption inhibition in the management of dyslipidemia. Curr Atheroscler Rep. 2004;6: 52-59.
36. Fonarow GC, Watson KE. High-density lipoprotein cholesterol as a therapeutic target to reduce cardiovascular events. Am Heart J. 2004;147:939-941.
37. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-2497.
38. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation. 2001;104:2498-2502.
39. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515.
40. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.